#Cancer facer creator sub full#
#Cancer facer creator sub trial#

Smith has authored or co-authored include. Smith’s research has been presented extensively at national and international conferences. Smith has also served as a member of technical advisory groups for the National Colorectal Cancer Roundtable and the World Health Organization.ĭr.

#Cancer facer creator sub full#

She previously represented CDC’s National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP) on the Prevention and Control Sub-Committee and the Full Committee for the Charles C. Smith is the former chair of DCPC’s Health Disparities Work Group and Translation to Practice Work Group. Smith is a peer reviewer for several academic journals and from 2017 to 2021, she was a member of the national program committee for the American Psychosocial Oncology Society Annual Conference. The new intervention, Face Your Health, was developed in collaboration with a work group of community health workers and community health worker administrators from across the United States.ĭr. Smith recently completed an adaptation of AMIGAS for African American women who have rarely or never been screened for cervical cancer. AMIGAS was featured as a Community Guide in Action story for its use of evidence-based research.

In recognition of these achievements, AMIGAS was awarded the CDC/ATSDR Honor Award for Health Equity.

#Cancer facer creator sub trial#

A randomized controlled trial demonstrated the intervention’s effectiveness and cost effectiveness. Smith is a co-creator of AMIGAS, a theory-based and evidence-based bilingual educational outreach intervention designed to help promotoras (community health workers) and other lay health educators increase cervical cancer screening among Hispanic women who have rarely or never been screened for cervical cancer. She collaborates with various partners, agencies, organizations, and institutions and works extensively with collaborators throughout many communities in the United States.ĭr. Smith’s research investigates the multilevel determinants that influence cancer-related health inequities among patients, cancer survivors, and caregivers. Smith has led a team of behavioral scientists, epidemiologists, statisticians, and fellows dedicated to examining cancer-related health outcomes and translating research findings into public health practice and programs. Smith was a National Institutes of Health post-doctoral fellow in the Department of Medicine and the Department of Psychiatry at the University of Chicago.įor more than a decade, Dr. “If you are a stage 1 patient, you might not have to go through chemo, our test helps determine that decision,” Dr Manjiri Bakre, founder of OncoStem told ET.Judith Lee Smith, PhD, is a Senior Behavioral Scientist and Team Lead in the Division of Cancer Prevention and Control’s Epidemiology and Applied Research Branch. Her conviction for backing Oncostem is also because on the cost efficient way of addressing the issue of chemotherapy. Her bet on UE’s iBreastExam device is based on the uncomfortable experience women face with mammograms.

So you can tailor-make therapy, which are less harsh and for that early detection is very important.” “Cancer therapy is not one-size-fits-all, if you stratify them based on genomics, among other things. “Mine is just an ignition grant, but these devices are the future,” Shaw told ET.

In the last six months, she has been mentoring some healthcare startups in building business models, besides giving growth fund to Bangalore-based Oncostem Diagnostics that uses tumour cells of patients to determine the need of chemotherapy for treatment. UE Lifesciences is not the only company Shaw has placed her bets on.